4. 联合科研与学术交流：双方将整合内地与澳门专家资源，共同推动脑健康医学中心建设，并开展相关 临床研究与合作，提升区域学术影响力。 董事会认为，此次合作对集团具有以下战略意义： 1. 树立标杆，开拓湾区市场：与澳门最具影响力的私立医院建立合作，成功打造了集团数字疗法在港澳 地区的首个标杆项目，为後续在粤港澳大湾区其他城市的拓展提供了可复制的示范模式。 格隆汇2月8日丨脑动极光-B(06681.HK)宣布，公司间接全资附属公司－脑动极光医学科技数智(澳门)有 限公司(「脑动极光澳门」)，已于近期与澳门镜湖医院(「镜湖医院」)正式签署《脑健康数字AI技术服 务合作协议》。双方将围绕认知障碍的数字筛查、评估、训练及全程健康管理，在澳门地区建立长期战 略合作关系，共同构建覆盖「医院 － 社区 － 家居」的全链条脑健康服务新模式。 根据该协议，此次合作将围绕以下核心内容展开： 1. 共建「健脑中心」与服务体系：双方将基于集团的「六六脑科学健脑云服务」平台，在镜湖医院内设 立并运营「健脑中心」。该中心将提供从早期筛查、精准评估到数字化认知训练及病程随访的一站式服 务，构建镜湖医院内部「早期筛查 － 精准诊断 － 多学科 ...

Core Insights - The Guangdong province is aiming to achieve a trillion-level biopharmaceutical and health industry by leveraging policy support, capital assistance, and technological innovation [3][4][6]. Group 1: Industry Development - Guangdong's biopharmaceutical industry is at a critical development stage, with Guangzhou and Shenzhen as core hubs, supported by cities like Zhuhai and Zhongshan [4]. - The province has a strong foundation in traditional Chinese medicine (TCM), with a total industrial output value of 45.71 billion yuan in 2024, of which over 33.43 billion yuan comes from traditional Chinese medicine products, accounting for over 11% of the national total [8]. - The province faces challenges such as the degradation of medicinal material sources and low rates of secondary development for high-quality traditional Chinese medicine products, with less than 35% of products undergoing secondary development [8][9]. Group 2: Policy and Investment - Guangzhou is establishing a biopharmaceutical industry investment fund with a target scale of 20 billion yuan to support enterprise growth and optimize regulatory processes [6]. - Experts emphasize the need for long-term capital support for innovative drug development, advocating for the establishment of a comprehensive mother fund system to align with social capital [12][13]. - The current investment cycle for innovative drugs is long, and there is a call for government and market-based funds to adopt longer-term capital models to better serve the biopharmaceutical industry [12][13]. Group 3: Innovation and Collaboration - The Southern Metropolis Daily has initiated a deep research project focusing on the innovation capabilities of the biopharmaceutical and health industry, covering five major regions and evaluating companies based on innovation, transformation, and collaboration [6][9]. - Experts suggest building collaborative innovation platforms and promoting industry-academia-research alliances to enhance the biopharmaceutical ecosystem [15]. - The integration of AI in healthcare and biopharmaceuticals is seen as a transformative force, although challenges such as data silos and collaborative ecosystems remain [16]. Group 4: Market Trends and Opportunities - Chinese biopharmaceutical companies are increasingly gaining international attention, with 40% of major BD transactions in the first seven months of the year involving Chinese firms, up from 4-5% four years ago [16]. - Traditional pharmaceutical companies are transitioning to innovative biopharmaceutical enterprises, with significant R&D investments, exemplified by a company that allocated 22.4% of its revenue to R&D last year [17].

Group 1 - Shanghai's new materials industry has made significant breakthroughs in technological innovation over the past year, focusing on three major innovation hubs: fibers, membranes, and bio-manufacturing [1] - The Shanghai Municipal Science and Technology Commission is promoting comprehensive innovation and support for key technologies in leading, key, and future industries, aiming to enhance the core competitiveness of enterprises [1] - The high-quality development conference for the general new materials industry was held in the South Shanghai Science and Technology Innovation Center, emphasizing the importance of advanced materials as part of Shanghai's "3+6" industrial system [1] Group 2 - The Fengxian District has identified general new materials as one of its four leading industries, implementing effective measures to enhance industrial competitiveness and promote high-end industrial chain development [2] - A three-year action plan (2025-2027) for the development of the general new materials industry was released, outlining nine major actions to elevate industry capabilities and support key technology breakthroughs [2] - A collaborative initiative was signed among various educational and research institutions to deepen cooperation and promote the integration of technological and industrial innovation [2] Group 3 - A strategic cooperation framework agreement was signed to enhance financing services and attract capital to nurture potential enterprises in the new materials sector [3] - A supply-demand matching event for the new materials industry was held, where universities presented their latest research outcomes and companies conducted project roadshows [3] - Fengxian District aims to build a collaborative development platform integrating government, industry, academia, research, and application to inject new momentum into the high-quality development of the general new materials industry [3]